Catalog No.: PC-49860Not For Human Use, Lab Use Only.
FT-6876 (FT 6876) is a potent, selective, orally active CBP/p300 bromodomains inhibitor with IC50 of 5/2 nM, respectively, >500-fold selectivity over BRD4 (IC50=2,320 nM) and other bromodomains.
FT-6876 (FT6876) is a potent, selective, orally active CBP/p300 bromodomains inhibitor with IC50 of 5/2 nM, respectively, >500-fold selectivity over BRD4 (IC50=2,320 nM) and other bromodomains.
FT-6876 inhibits proliferation of AR+ breast cancer cell line MDA-MB-453 (IC50=197 nM).
FT-6876 also potently inhibits the proliferation of AR+ prostate cancer models including the AR-v7 expressing 22Rv1 cells (IC50=600 nM).
FT-6876 is more than 40 times as potent as enzalutamide against MDA-MB-453 cells and preferentially active against breast cancer cell lines expressing high levels of AR.
FT-6876 (10 uM) induces the rapid reduction of H3K27Ac in MDA-MB-453 cells.
FT-6876 modulates ER and AR target genes in MDA-MB-453 cells.
FT-6876 (30 mg/kg, p.o) induced tumor stasis in this model of AR+ TNBC, with reduction of H3K27 and proliferation index.
